Overall Rating
Stock is in a solid downturn.
Stock's dividend yield is above average.
This rating is directly related to the length and consistency of a company's dividend payouts.
Dividend payouts are consistent, but increases small.
Earnings estimates have been cut slightly.
Recent Headlines
- Merck to Layoff Nearly 13% of its Workforce; Profits Plunge in Q3 Earnings Report (MRK)
Wed, Oct 22, 2008 - Merck Offers No Guidance (MRK)
Tue, Jul 22, 2008 - Dividend Stock Recommendation Changes (TKR, USB, MRK)
Mon, Jul 21, 2008 - Schering Gets Plowed (SGP)
Mon, Jul 21, 2008 - Is Pfizer's High Yield a Dividend Trap?
Wed, Jun 25, 2008
Profile & Recommendation
Company Profile
Merck (MRK) - pharmaceutical giant's drugs are used in the treatment of cardiovascular ailments, hypertension, high cholesterol, inflammation, glaucoma, ulcers, hepatitis, and Parkinsons disease. Here are some of the familiar names. It offers Singulair for treating asthma, and relief of symptoms of allergic rhinitis; Cozaar/Hyzaar and Vasotec for the treatment of hypertension/heart failure; Fosamax and Fosamax Plus D for the treatment and prevention of osteoporosis; Zocor, an atherosclerosis product; Primaxin and Cancidas, anti-bacterial/anti-fungal products; Cosopt and Trusopt, the ophthalmological products; Proscar, an urology product for the treatment of symptomatic benign prostate enlargement; Maxalt, an acute migraine product; and Propecia for the treatment of male pattern hair loss. The company offers Varivax to prevent chickenpox; M-M-R II, for the treatment of measles, mumps, and rubella; ProQuad, a pediatric combination vaccine against measles, mumps, rubella, and varicella; Gardasil for the prevention of cervical cancer and genital warts; Pneumovax for the prevention of pneumococcal diseases; RotaTeq for the protection against rotavirus gastroenteritis in infants and children; and Zostavax, a vaccine for the prevention of shingles. The company was founded in 1891 and is headquartered in Whitehouse Station, New Jersey.
Based on our rating criteria, this stock has achieved a "Neutral" rating. Stocks with a neutral rating are considered mediocre investments in terms of expected price growth and dividend payments.
Stock Notes
This large cap stock does not make an attractive dividend stock investment at this time.





Direct Competitors
RSS Feeds